Assessing severity of patients with community-acquired pneumonia

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 3, 2012, Pages 272-283

  Pereira, Jose Manuel ^a   Paiva, Jose Artur ^a   Rello, Jordi ^b  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

bacterial load; biomarkers; community acquired pneumonia; DNAemia; scores; severity

Indexed keywords

BACTERIAL DNA; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COPEPTIN; D DIMER; GLUCOSE; HYDROCORTISONE; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; PROADRENOMEDULLIN; PROCALCITONIN; SODIUM; UNCLASSIFIED DRUG;

ACIDEMIA; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; ARTICLE; BACTEREMIA; BACTERIAL LOAD; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONFUSION; CRB 65; CURB 65; DISEASE SEVERITY; GOLD STANDARD; HEMATOCRIT; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; HYPOTHERMIA; HYPOXEMIA; INFECTIOUS DISEASES SOCIETY OF AMERICA AMERICANTHORACIC SOCIETY; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOPENIA; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NURSING HOME PATIENT; PATIENT CARE; PLEURA EFFUSION; PREDICTION; PREDISPOSITION INSULT RESPONSE ORGAN DYSFUNCTION COMMUNITY ACQUIRED PNEUMONIA; PRIORITY JOURNAL; SCAP; SENSITIVITY AND SPECIFICITY; SMART COP; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA; UREMIA;

BACTERIAL LOAD; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; DECISION SUPPORT TECHNIQUES; DNA, BACTERIAL; HUMANS; PNEUMONIA; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84862493752     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1315639     Document Type: Article

References (112)

1. Osler W. The Principles and Practice of Medicine: Designed for the Use of Practitioners and Students of Medicine. New York, NY D. Appleton: 1892
2. Angus DC, Marrie TJ, Obrosky DS., et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med: 2002; 166 5 717 723 (Pubitemid 34971856)
3. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest: 2003; 123 5 1503 1511 (Pubitemid 36549769)
4. Bodí M, Rodríguez A, Solé-Violán J., et al. Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis: 2005; 41 12 1709 1716 (Pubitemid 41759852)
5. Kamath A, Pasteur MC, Slade MG, Harrison BD. Recognising severe pneumonia with simple clinical and biochemical measurements. Clin Med: 2003; 3 1 54 56 (Pubitemid 36232190)
6. Myint PK, Kamath AV, Vowler SL, Maisey DN, Harrison BD.; British Thoracic Society. Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? A compilation study of two prospective cohorts. Age Ageing: 2006; 35 3 286 291
7. Lim WS, van der Eerden MM, Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax: 2003; 58 5 377 382 (Pubitemid 36560938)
8. Rodríguez A, Mendia A, Sirvent JM., et al. CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med: 2007; 35 6 1493 1498 (Pubitemid 46809312)
9. Mandell LA, Wunderink RG, Anzueto A., et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis: 2007; 44 02 S27 S72 (Pubitemid 46290553)
10. Lim WS, Baudouin SV, George RC., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax: 2009; 64 03 iii1 55
11. Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J: 2007; 30 3 556 573 (Pubitemid 351182082)
12. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: a review. QJM: 2009; 102 6 379 388
13. Tang CM, Macfarlane JT. Early management of younger adults dying of community acquired pneumonia. Respir Med: 1993; 87 4 289 294 (Pubitemid 23194336)
14. Neill AM, Martin IR, Weir R., et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax: 1996; 51 10 1010 1016 (Pubitemid 26360177)
15. McQuillan P, Pilkington S, Allan A., et al. Confidential inquiry into quality of care before admission to intensive care. BMJ: 1998; 316 7148 1853 1858 (Pubitemid 28276929)
16. Fine MJ, Auble TE, Yealy DM., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med: 1997; 336 4 243 250 (Pubitemid 27044625)
17. Man SY, Lee N, Ip M., et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax: 2007; 62 4 348 353 (Pubitemid 46580578)
18. Buising KL, Thursky KA, Black JF., et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax: 2006; 61 5 419 424 (Pubitemid 43723326)
19. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med: 2008; 121 3 219 225 (Pubitemid 351317927)
20. Aujesky D, Auble TE, Yealy DM., et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med: 2005; 118 4 384 392 (Pubitemid 40460997)
21. Chalmers JD, Mandal P, Singanayagam A., et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med: 2011; 37 9 1409 1420
22. Muller MP, McGeer AJ, Hassan K, Marshall J, Christian M.; Toronto Invasive Bacterial Disease Network. Evaluation of pneumonia severity and acute physiology scores to predict ICU admission and mortality in patients hospitalized for influenza. PLoS ONE: 2010; 5 3 e9563
23. Brandão-Neto RA, Goulart AC, Santana AN., et al. The role of pneumonia scores in the emergency room in patients infected by 2009 H1N1 infection. Eur J Emerg Med: 2011; Jul 22. [Epub ahead of print] PubMed
24. Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax: 2008; 63 8 698 702
25. Capelastegui A, España PP, Quintana JM., et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J: 2006; 27 1 151 157 (Pubitemid 43092679)
26. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T.; CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med: 2006; 260 1 93 101 (Pubitemid 43894075)
27. Ewig S, Welte T. CRB-65 for the assessment of pneumonia severity: who could ask for more? Thorax: 2008; 63 8 665 666
28. Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJ. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Arch Intern Med: 2008; 168 13 1465 1468 (Pubitemid 352008428)
29. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax: 2010; 65 10 884 890
30. Mortensen EM, Coley CM, Singer DE., et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med: 2002; 162 9 1059 1064 (Pubitemid 34492537)
31. Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis: 2003; 37 12 1617 1624 (Pubitemid 37549947)
32. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest: 2010; 137 3 552 557
33. Niederman MS, Mandell LA, Anzueto A., et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med: 2001; 163 7 1730 1754 (Pubitemid 32578779)
34. Brown SM, Jones BE, Jephson AR, Dean NC.; Infectious Disease Society of America/American Thoracic Society 2007. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med: 2009; 37 12 3010 3016
35. Phua J, See KC, Chan YH., et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax: 2009; 64 7 598 603
36. Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med: 2009; 27 8 968 974
37. Liapikou A, Ferrer M, Polverino E., et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis: 2009; 48 4 377 385
38. Chalmers JD, Taylor JK, Mandal P., et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis: 2011; 53 6 503 511
39. Charles PGP, Wolfe R, Whitby M., et al. Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis: 2008; 47 3 375 384 (Pubitemid 352009359)
40. Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis: 2008; 47 12 1571 1574
41. España PP, Capelastegui A, Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med: 2006; 174 11 1249 1256 (Pubitemid 44924826)
42. Yandiola PP, Capelastegui A, Quintana J., et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest: 2009; 135 6 1572 1579
43. Miyashita N, Matsushima T, Oka M.; Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med: 2006; 45 7 419 428 (Pubitemid 43676577)
44. Buising KL, Thursky KA, Black JF., et al. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas: 2007; 19 5 418 426 (Pubitemid 47547572)
45. Shindo Y, Sato S, Maruyama E., et al. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology: 2008; 13 5 731 735 (Pubitemid 351977599)
46. Kohno S, Seki M, Watanabe A.; CAP Study Group. Evaluation of an assessment system for the JRS 2005: A-DROP for the management of CAP in adults. Intern Med: 2011; 50 11 1183 1191
47. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med: 2009; 37 2 456 462
48. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med: 1981; 9 8 591 597
49. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med: 1985; 13 10 818 829 (Pubitemid 15250137)
50. Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. QJM: 2001; 94 10 521 526 (Pubitemid 32998342)
51. Lim WS. Severity assessment in community-acquired pneumonia: moving on. Thorax: 2007; 62 4 287 288
52. Woodhead M. Assessment of illness severity in community acquired pneumonia: a useful new prediction tool? Thorax: 2003; 58 5 371 372 (Pubitemid 36564822)
53. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med: 1992; 20 6 864 874
54. Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. QJM: 2001; 94 10 521 526 (Pubitemid 32998342)
55. Subbe CP, Davies RG, Williams E, Rutherford P, Gemmell L. Effect of introducing the Modified Early Warning score on clinical outcomes, cardio-pulmonary arrests and intensive care utilisation in acute medical admissions. Anaesthesia: 2003; 58 8 797 802 (Pubitemid 36934576)
56. McBride J, Knight D, Piper J, Smith GB. Long-term effect of introducing an early warning score on respiratory rate charting on general wards. Resuscitation: 2005; 65 1 41 44 (Pubitemid 40417453)
57. Barlow GD, Nathwani D, Davey PG. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax: 2007; 62 3 253 259 (Pubitemid 46579808)
58. Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest: 2006; 129 4 968 978
59. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med: 1985; 13 10 818 829 (Pubitemid 15250137)
60. Kollef KE, Reichley RM, Micek ST, Kollef MH. The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest: 2008; 133 2 363 369 (Pubitemid 351272393)
61. Spindler C, Ortqvist A. Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. Eur Respir J: 2006; 28 4 816 823 (Pubitemid 46332004)
62. Almirall J, Bolíbar I, Toran P., et al. Community-Acquired Pneumonia Maresme Study Group. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest: 2004; 125 4 1335 1342 (Pubitemid 38501347)
63. Hohenthal U, Hurme S, Helenius H., et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect: 2009; 15 11 1026 1032
64. Menéndez R, Martínez R, Reyes S., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax: 2009; 64 7 587 591
65. Lee JH, Kim J, Kim K., et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care: 2011; 26 3 287 294
66. Müller B, Harbarth S, Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis: 2007; 7 10
67. Müller B, Morgenthaler N, Stolz D., et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest: 2007; 37 2 145 152 (Pubitemid 46066494)
68. Christ-Crain M, Stolz D, Jutla S., et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med: 2007; 176 9 913 920 (Pubitemid 350097081)
69. Müller B, Süess E, Schuetz P., et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med: 2006; 260 6 568 576 (Pubitemid 44772377)
70. Krüger S, Papassotiriou J, Marre R., et al. CAPNETZ Study Group. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med: 2007; 33 12 2069 2078 (Pubitemid 350164580)
71. Christ-Crain M, Morgenthaler NG, Stolz D., et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care: 2006; 10 3 R96 R103
72. Masiá M, Gutiérrez F, Shum C., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest: 2005; 128 4 2223 2229 (Pubitemid 41507563)
73. Krüger S, Ewig S, Marre R., et al. CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J: 2008; 31 2 349 355
74. Huang DT, Weissfeld LA, Kellum JA., et al. GenIMS Investigators. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med: 2008; 52 1 48 58, e2
75. Querol-Ribelles JM, Tenias JM, Grau E., et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest: 2004; 126 4 1087 1092 (Pubitemid 39391236)
76. Chalmers JD, Singanayagam A, Scally C, Hill AT. Admission D-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med: 2009; 53 5 633 638
77. Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med: 2005; 258 4 391 393 (Pubitemid 41368692)
78. Christ-Crain M, Breidthardt T, Stolz D., et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med: 2008; 264 2 166 176 (Pubitemid 351962572)
79. Gotoh S, Nishimura N, Takahashi O., et al. Adrenal function in patients with community-acquired pneumonia. Eur Respir J: 2008; 31 6 1268 1273
80. Kolditz M, Halank M, Schulte-Hubbert B, Höffken G. Adrenal function is related to prognosis in moderate community-acquired pneumonia. Eur Respir J: 2010; 36 3 615 621
81. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest: 1973; 52 9 2340 2352
82. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension: 1983; 5 2 Pt 2 I129 I138
83. Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem: 1999; 45 1 98 103 (Pubitemid 29036391)
84. Hirata Y, Mitaka C, Sato K., et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab: 1996; 81 4 1449 1453 (Pubitemid 26118575)
85. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides: 2001; 22 11 1693 1711 (Pubitemid 34062786)
86. Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci: 2000; 66 10 855 872 (Pubitemid 30084473)
87. Kato J, Tsuruda T, Kitamura K, Eto T. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res: 2003; 26 Suppl S113 S119 (Pubitemid 36372326)
88. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides: 2004; 25 8 1369 1372 (Pubitemid 39180069)
89. Huang DT, Angus DC, Pugh NA et al. Proadrenomedullin in Emergency Department patients with community-acquired pneumonia. Ann Emerg Med: 2008; 52 04 S41
90. Schuetz P, Wolbers M, Christ-Crain M., et al. ProHOSP Study Group. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care: 2010; 14 3 R106
91. Prat C, Lacoma A, Dominguez J., et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect: 2007; 55 5 400 407 (Pubitemid 47611511)
92. Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem: 2007; 53 12 2193 2201 (Pubitemid 350197304)
93. Claessens YE, Mathevon T, Kierzek G., et al. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intensive Care Med: 2010; 36 5 799 809
94. Krüger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T.; CAPNETZ Study Group. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax: 2010; 65 3 208 214
95. Vazquez M, Jockers K, Christ-Crain M, Zimmerli W, Müller B, Schuetz P. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: a prospective validation study. Int J Cardiol: 2010; 156 1 16 23
96. Prat C, Lacoma A, Dominguez J., et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect: 2007; 55 5 400 407 (Pubitemid 47611511)
97. Uchida T, Shirasawa M, Ware LB., et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med: 2006; 173 9 1008 1015
98. Angus DC, Yang L, Kong L., et al. GenIMS Investigators. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med: 2007; 35 4 1061 1067 (Pubitemid 46598956)
99. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med: 2004; 350 5 451 458 (Pubitemid 38133765)
100. Feldman C, Kallenbach JM, Levy H, Thorburn JR, Hurwitz MD, Koornhof HJ. Comparison of bacteraemic community-acquired lobar pneumonia due to Streptococcus pneumoniae and Klebsiella pneumoniae in an intensive care unit. Respiration: 1991; 58 5-6 265 270
101. Brogly N, Devos P, Boussekey N, Georges H, Chiche A, Leroy O. Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J Infect: 2007; 55 2 136 140 (Pubitemid 47044751)
102. Mirsaeidi M, Peyrani P, Aliberti S., et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest: 2010; 137 2 416 420
103. Landsman JB. Bacteriaemia and prognosis in lobar pneumonia: the results of quantitative blood culture in pneumococcus pneumonia. Glasg Med J: 1952; 33 2 33 45
104. Christie IM. Bacteraemia in lobar pneumonia. Lancet: 1933; 2 804 805
105. Carrol ED, Guiver M, Nkhoma S., et al. IPD Study Group. High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease. Pediatr Infect Dis J: 2007; 26 5 416 422 (Pubitemid 46789323)
106. Peters RP, van Agtmael MA, Gierveld S., et al. Quantitative detection of Staphylococcus aureus and Enterococcus faecalis DNA in blood to diagnose bacteremia in patients in the intensive care unit. J Clin Microbiol: 2007; 45 11 3641 3646 (Pubitemid 350156861)
107. Ho YC, Chang SC, Lin SR, Wang WK. High levels of mecA DNA detected by a quantitative real-time PCR assay are associated with mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol: 2009; 47 5 1443 1451
108. Peters RP, de Boer RF, Schuurman T., et al. Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia. J Clin Microbiol: 2009; 47 10 3308 3312
109. Chuang YC, Chang SC, Wang WK. High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy. PLoS ONE: 2010; 5 11 e14133
110. Muñoz-Almagro C, Gala S, Selva L, Jordan I, Tarragó D, Pallares R. DNA bacterial load in children and adolescents with pneumococcal pneumonia and empyema. Eur J Clin Microbiol Infect Dis: 2011; 30 3 327 335
111. Kim DM, Jung SI, Jang HC., et al. Vibrio vulnificus DNA load and mortality. J Clin Microbiol: 2011; 49 1 413 415
112. Rello J, Lisboa T, Lujan M., et al. DNA-Neumococo Study Group. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest: 2009; 136 3 832 840